Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer

NCT00892736 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00892736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00892736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
April 20, 2009
Completion date
May 19, 2017
Enrollment
98 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

basal-like breast carcinoma, brca1 mutation carrier, brca2 mutation carrier, breast carcinoma, estrogen receptor negative, her2/neu negative, hereditary breast and ovarian cancer syndrome, ovarian carcinoma, pancreatic carcinoma, progesterone receptor negative, prostate carcinoma, recurrent breast carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, solid neoplasm, triple-negative breast carcinoma